Key points are not available for this paper at this time.
Introduction/Background Ovarian cancer is the most fatal gynecologic cancer, with approximately 50% of cases being diagnosed at an advanced stage. The standard treatment typically involves complete cytoreductive surgery through laparotomy, followed by platinum-based chemotherapy. Recent studies have suggested that neoadjuvant chemotherapy followed by interval debulking surgery in advanced-stage ovarian cancer, offering comparable survival rates with lower morbidity and mortality. Besides, there has been a growing interest in exploring minimally invasive surgery as a safe and feasible alternative for patients who exhibit a complete response to neoadjuvant chemotherapy. Here, we propose a surgical procedure for single port robot-assisted interval cytoreductive surgery for advanced ovarian cancer. Methodology This is a video presentation of single port robotic interval cytoreductive surgery for advanced ovarian cancer. The patient was a 55-year-old woman (body mass index 24.99kg/m²) who was diagnosed with high-grade serous carcinoma through previous diagnostic laparoscopy. The preoperative computed tomography/magnetic resonance imaging showed multiple metastatic lymph nodes in left para-aortic, common iliac and external iliac chain, presenting FIGO stage IIIC. After 3 cycles of platinum based neoadjuvant chemotherapy, the surgery was performed. Results The surgery was performed including robot-assisted hysterectomy with both salpingo-oophorectomy, left pelvic LN dissection, para-aortic lymph node dissection and omentectomy. The operation was performed without residual disease, satisfying R0 resection. The operation was performed successfully with no intraoperative or postoperative complications. Total duration of surgery was 300 minutes. The estimated blood loss was 200 mL. The patient was discharged on day 3. Conclusion This is a case demonstrating the safety and feasibility of minimally single port robot-assisted interval cytoreductive surgery after neoadjuvant chemotherapy in advanced ovarian cancer, without severe adverse effects. Disclosures I have no potential conflict of interest to report.
Hwang et al. (Fri,) studied this question.